A “likely pathogenic” result on a genetic test means the laboratory has determined, with at least 90 percent confidence, that the variant found in your DNA is capable of causing disease. It sits one step below “pathogenic” on a five-tier classification scale used by genetics laboratories worldwide, and for most clinical purposes it is treated the same way. But that remaining sliver of uncertainty matters, and understanding what it means for your health, your family, and any decisions ahead requires more than a one-line definition.
The Five-Tier System Behind the Label
When a lab sequences your DNA and finds a variant, it does not simply call it “good” or “bad.” Since 2015, clinical genetics laboratories in the United States and many other countries have followed guidelines jointly developed by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP). Those guidelines place every variant into one of five categories: pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, or benign. The word “likely” in both the pathogenic and benign categories was defined to mean greater than 90 percent certainty that the variant is disease-causing or harmless, respectively. That threshold is somewhat arbitrary, but it gives laboratories and clinicians a shared benchmark for how much evidence is enough to act on.
In practice, clinical teams generally manage patients with likely pathogenic variants the same way they manage those with confirmed pathogenic variants. If you carry a likely pathogenic BRCA2 variant, for instance, your oncologist will typically recommend the same screening and risk-reduction options as for someone whose variant has been definitively confirmed. The distinction matters more to the laboratory than to your immediate care plan, because it flags the fact that additional data could, in theory, shift the classification.
What Kind of Evidence Goes Into the Call
Laboratories do not assign these labels by gut feeling. The ACMG/AMP framework lays out specific types of evidence, each weighted as “strong,” “moderate,” or “supporting,” that get combined to reach a final classification. The evidence falls into several broad buckets.
- Population frequency: If a variant is common in healthy people across major ancestral groups, it is unlikely to cause serious disease. Reference databases like gnomAD help labs filter out common variants by checking allele frequency across continental populations.
- Functional data: Laboratory experiments that measure what a variant actually does to a protein can provide strong evidence for or against pathogenicity. Current guidelines incorporate functional assay results alongside computational predictions of how a variant alters protein structure or function.
- Computational predictions: Software tools estimate whether an amino acid change is likely to damage a protein. When multiple tools agree, their combined weight counts as supporting evidence, roughly doubling the odds in favor of pathogenicity or benignity.
- Clinical and family data: Whether the variant tracks with disease in affected family members, or whether it has been reported in unrelated patients with the same condition, adds to the case.
A variant reaches “likely pathogenic” when the combined weight of these evidence types clears the 90 percent threshold but falls short of the bar for a definitive “pathogenic” call. Often this happens when functional studies are strong but the variant has not yet been reported in enough unrelated patients, or when population data are sparse for the relevant ancestry group.
Why a Likely Pathogenic Variant Does Not Guarantee You Will Get Sick
One of the most common sources of confusion after receiving a likely pathogenic result is the assumption that the variant will inevitably cause disease. In genetics, the connection between carrying a variant and developing symptoms is called penetrance, and it is rarely 100 percent. The same genetic variant found in different people can produce a wide spectrum of outcomes, from no noticeable symptoms at all to severe disease, even within the same family.
This phenomenon, known as incomplete penetrance and variable expressivity, is a major challenge in interpreting genetic results. A large-scale analysis of over 800,000 individuals in the Genome Aggregation Database confirmed that the absence of a disease phenotype in someone carrying a disease-associated variant is common, not exceptional.
What this means for you in concrete terms: a likely pathogenic result in a cancer gene does not mean you will develop cancer. It means your risk is elevated compared to someone without the variant, and that elevated risk justifies closer surveillance, possibly preventive measures, and definitely a conversation with a genetic counselor or specialist who can put the numbers in context for your specific gene, variant, and personal history.
Variants Can Change Categories Over Time
Genetic variant classification is not permanent. As researchers study more people, publish more functional data, and expand population databases, laboratories periodically re-evaluate variants and sometimes reclassify them. A large study tracking over two million variants across eight years of clinical testing found that roughly 4.6 percent were reclassified during that period, producing over 105,000 reclassification events. The majority of those events involved variants of uncertain significance being moved into a definitive category, either likely benign/benign or likely pathogenic/pathogenic.
Reclassification can go in either direction. A variant labeled likely pathogenic today could be upgraded to pathogenic as more families with the same variant are studied. Less commonly, new evidence could downgrade it to a VUS if, say, it turns out to be more common in healthy populations than originally thought. The rate of downgrade from likely pathogenic is low, but it happens, and it is one reason genetic counselors encourage periodic check-ins rather than treating a single report as the final word.
When Different Labs Disagree
If you have ever looked at ClinVar, the public database where clinical laboratories share their variant classifications, you may have noticed that different labs sometimes assign different categories to the same variant. Most of the time classifications are consistent, but discrepancies exist. An analysis of classification differences across 41 clinical laboratories found that the most frequent disagreements occur between VUS and benign categories, rather than between benign and pathogenic.
In other words, true one-step disagreements (likely pathogenic versus VUS) happen but are far less common than the gray-zone disagreements at the benign end of the spectrum. Still, if you have results from two different labs and they do not match, that is worth raising with your clinician or genetic counselor. The labs may be working from different evidence or applying different interpretive thresholds, and a specialist can help sort out which classification is best supported.
Ancestry Matters More Than Most People Realize
The databases that laboratories rely on to classify variants were built predominantly from people of European descent. That historical imbalance has real consequences. People from non-European backgrounds experience higher rates of uncertain classifications, and some variants have been misclassified as likely pathogenic when they are actually benign in certain populations. A landmark study identified multiple individuals, all of African or unspecified ancestry, who had received positive genetic test reports based on variants that were later recognized as benign. The errors traced back not to failures in care access or biology, but to the lack of diverse control populations in early genetic research.
The problem is measurable and ongoing. A study of hereditary disease testing found that VUS rates were higher among Asian, Black, Native American, Pacific Islander, and Sephardic Jewish individuals compared to those identified as White. In the cardiovascular genetics space specifically, researchers found that more than a third of all pathogenic or likely pathogenic variants that were later downgraded to VUS had been relatively common among individuals of non-European ancestry. Only about 1.6 percent of the downgraded variants were common in people of European ancestry.
If you are from an underrepresented background and receive a likely pathogenic result, the classification is still probably correct, but the margin of uncertainty is wider than it would be for someone whose ancestry is well represented in reference databases. A genetic counselor familiar with these disparities can help interpret your result in the appropriate context.
What Happens After You Get the Result
A likely pathogenic finding typically triggers a cascade of next steps, and the specifics depend on the gene, the condition, and your personal and family history.
The most immediate step is usually a conversation with a genetic counselor, if one was not already involved. Genetic counselors specialize in translating lab reports into actionable information. They can explain what the specific variant means for your health risks, walk you through surveillance and prevention options, and coordinate with your other physicians.
For many conditions, particularly hereditary cancer syndromes and cardiac disorders, guidelines recommend that close blood relatives be offered testing for the same variant. This is called cascade testing. If you carry a likely pathogenic BRCA1 variant, for example, your first- and second-degree relatives (parents, siblings, children, aunts, uncles, nieces, nephews) are generally advised to undergo genetic counseling and targeted testing. Identifying carriers in the family before they develop symptoms can be genuinely lifesaving, because it allows for earlier screening and, in some cases, preventive interventions.
In cancer genetics, a likely pathogenic result can also influence treatment decisions. Tumor profiling through next-generation sequencing is increasingly used not only to find somatic mutations that drive cancer growth but also to flag germline variants that were inherited. When a pathogenic or likely pathogenic germline variant is identified during tumor testing, consensus guidelines now increasingly recommend comprehensive follow-up germline testing, because the variant has implications for the patient’s broader cancer risk and for their relatives.
The Condition Shapes What the Result Means in Practice
Not all likely pathogenic variants carry the same weight. A likely pathogenic variant in a gene associated with a highly penetrant, early-onset condition demands a different response than one in a gene linked to a late-onset, lower-penetrance risk.
In hereditary cancer, for example, a likely pathogenic BRCA1 variant substantially raises lifetime breast and ovarian cancer risk, and the management options (enhanced screening, risk-reducing surgery, chemoprevention) are well established. A UK study of 152 patients undergoing multi-gene panel testing found that 10 percent carried a pathogenic or likely pathogenic variant in a cancer gene relevant to their personal or family history, and nearly half of those individuals would not have qualified for testing under the national eligibility criteria at the time. In other words, restricting testing to people who fit narrow criteria would have missed actionable results in a meaningful fraction of patients.
In cardiovascular genetics, the picture is shaped by genotype-specific differences. Research into arrhythmogenic cardiomyopathy, for instance, has shown that early signs of disease onset and risk factors for sudden cardiac death differ depending on which gene is affected. That means a likely pathogenic variant in one cardiac gene might call for a different surveillance strategy, or even a different medication, than the same classification in a different cardiac gene.
Direct-to-Consumer Test Results Need Clinical Confirmation
If your likely pathogenic result came from a direct-to-consumer (DTC) genetic testing company rather than a clinical-grade laboratory, there is an additional and critical step before you or your doctor act on it. A study examining raw data from DTC companies found that 40 percent of variants reported in genes with potential clinical impact were false positives, meaning the variant either was not actually present or was misclassified.
The technology used by most DTC companies (genotyping arrays) is designed for broad screening, not for the kind of precise variant detection that clinical sequencing provides. That does not mean DTC results are worthless, but it does mean any clinically significant finding needs to be confirmed in a diagnostic laboratory before it influences medical decisions. The researchers who uncovered the 40 percent false-positive rate were emphatic on this point: no changes to medical management should be made based on unconfirmed DTC raw data.
Talking to Family Members About Your Result
One of the more difficult aspects of a likely pathogenic result is that it has implications beyond your own health. Genetic variants are inherited, so your result carries information about your parents, siblings, and children. Sharing that information can be straightforward in some families and deeply complicated in others.
From a legal standpoint, the landscape is uneven. In the United States, the Genetic Information Nondiscrimination Act (GINA) protects against discrimination in health insurance and employment based on genetic information, but it does not cover life insurance, disability insurance, or long-term care insurance. The legal obligations that clinicians owe to at-risk relatives are limited and variable by state; the current consensus is that genetic counselors are generally not required to warn relatives directly about genetic risks.
What this means practically is that the responsibility for sharing information usually falls on you, the patient. Genetic counselors can help you think through how to approach those conversations, and some offer to write letters that you can share with family members to explain the result and recommend testing. The decision to share or not is personal, but the medical case for sharing is strong: cascade testing in families with known pathogenic or likely pathogenic variants is one of the most cost-effective interventions in preventive medicine.
Carrier Screening and Reproductive Context
A likely pathogenic variant can show up in a different context entirely: carrier screening before or during pregnancy. Carrier screening looks for variants in genes associated with autosomal recessive conditions, where a child would need to inherit a defective copy from each parent to be affected. If you are identified as a carrier of a likely pathogenic variant in a gene for cystic fibrosis, sickle cell disease, or any of dozens of other conditions, you are healthy yourself but could pass the variant to your children.
Current reproductive guidelines recommend offering expanded carrier screening that can cover tens to hundreds of conditions. A study of a diverse patient population found that the vast majority of respondents (91 percent) who received carrier screening results found them useful. However, only about 37 percent said they would actually change their reproductive plans if identified as being at risk. That gap between perceived utility and behavioral change underscores a reality of genetic information: knowing your status is valuable, but what you do with that knowledge is a deeply personal decision influenced by values, circumstances, and family planning goals that no lab report can dictate.
How Classification Accuracy Is Improving
The tools and data available to laboratories are improving rapidly. Population databases like gnomAD now include hundreds of thousands of individuals from diverse ancestral backgrounds, making it easier to filter out common benign variants that might previously have been flagged as suspicious. High-throughput functional assays can now test thousands of variants in a single experiment, generating the kind of data that previously took years of individual case reports to accumulate. A study evaluating 44 computational prediction tools against a truth set of over 9,400 missense variants found that the tools performed well when benchmarked against clinically validated functional assays, supporting their use as one piece of the evidence puzzle.
The net effect is that the gray zone is shrinking. More variants are moving out of the uncertain middle and into definitive categories. For patients who received a likely pathogenic result years ago, it may be worth asking whether the variant has been reclassified since their original report. Many laboratories have systems for recontacting patients or updating reports when significant reclassifications occur, but the process is not always automatic. Asking your genetic counselor to check the current status of your variant in ClinVar or to request an updated report from the testing laboratory is a reasonable step, especially if several years have passed.